


Please type a plus sign (+) inside this box → 

DEC 17 2002

PATENT & TRADEMARK OFFICE

Complete if Known

RECEIVED
DEC 18 2002
TECH CENTER 1600/2002

Substitute for form 1449A/B/PTO


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Application Number	09/376,487
Filing Date	August 18, 1999
First Named Inventor	MISHRA
Group Art Unit	1617
Examiner Name	E. Webman
Attorney Docket Number	402090/SKYE PHARMA

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	1	6,028,108		George	2/22/2000	
	2	6,140,374		May et al.	10/31/2000	
	3	6,140,373		May et al.	10/31/2000	
	4	6,147,122		Mirejovsky et al.	11/14/2000	
	5	6,177,477		George et al.	1/23/2001	
	6	6,197,323		Georgieff	3/6/2001	
	7	2001/0008889		Caruso et al.	7/19/2001	
	8	6,284,267		Aneja	9/4/2001	
	9	6,291,013		Gibson et al.	9/18/2001	
	10	2001/0025035		Stella et al.	9/27/2001	
	11	2001/0041923		Dobak, III	11/15/2001	
	12	6,322,810		Alkan-Onyuksel et al.	11/27/2001	
	13	2001/0051595		Lyons et al.	12/13/2001	
	14	2002/0002704		Davis et al.	1/3/2002	
	15	2002/0003179		Verhoff et al.	1/10/2002	
	16	2002/0016373		Bieniarz et al.	2/7/2002	
	17	2002/0017296		Hickle	2/14/2002	
	18	2002/0017299		Hickle	2/14/2002	
	19	2002/0017300		Hickle et al.	2/14/2002	
	20	2002/0022667		Pace et al.	2/21/2002	
	21	2002/0025337		Illum et al.	2/28/2002	
	22	2002/0032171		Chen et al.	3/14/2002	
	23	2002/0035141		Attala	3/21/2002	
	24	2002/0035161		Segura et al.	3/21/2002	
	25	2002/0037933		Basu et al.	3/28/2002	
	26	6,365,190		Gordon et al.	4/2/2002	
	27	6,368,619		New et al.	4/9/2002	
	28	2002/0047058		Verhoff et al.	4/25/2002	
	29	2002/0058009		Bartus et al.	5/16/2002	
	30	2002/0068764		Franks et al.	6/6/2002	
	31	2002/0071852		Deckers et al.	6/13/2002	
	32	2002/0082252		Hochman	6/27/2002	
	33	6,413,527		Simonnet et al.	7/2/2002	
	34	6,419,949		Gasco	7/16/2002	
	35	2002/0102217		Klaveness et al.	8/1/2002	
	36	2002/0102216		Lanza et al.	8/1/2002	
	37	2002/0102215		Klaveness et al.	8/1/2002	

Examiner Signature




Date Considered



6/04

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

DEC 17 2002



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Sheet	2	of	2	Application Number	09/376,487
				Filing Date	August 18, 1999
				First Named Inventor	MISHRA
				Group Art Unit	1617
				Examiner Name	E. Webman
				Attorney Docket Number	402090/SKYE PHARMA

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
H	38	2002/0102281		Auberger et al.	8/1/2002	
	39	2002/0107291		De Tommaso	8/8/2002	
	40	2002/0107265		Chen et al.	8/8/2002	
	41	6,433,040		Dellamary et al.	8/13/2002	
	42	6,436,367		Modi	8/20/2002	
	43	6,436,430		Mulye	8/20/2002	
	44	2002/0115609		Onyuksel et al.	8/22/2002	
	45	6,440,456		Nguyen et al.	8/27/2002	
	46	6,440,493		Gibson et al.	8/27/2002	
	47	2002/0120015		Dennis et al.	8/29/2002	
	48	2002/0120002		Baker et al.	8/29/2002	
	49	6,444,859		Bieniarz et al.	9/3/2002	
	50	2002/0128698		Dobak, III et al.	9/12/2002	
	51	6,451,339		Patel et al.	9/17/2002	
	52	2002/0142093		Gibson et al.	10/3/2002	
	53	6,464,987		Fanara et al.	10/15/2002	
	54	2002/0150621		Kohane et al.	10/17/2002	
	55	6,469,069		Mirejovsky et al.	10/22/2002	
	56	2002/0160043		Coleman	10/31/2002	
g	57	6,475,506		Inoue et al.	11/5/2002	
	58	2002/0173547		Jones et al.	11/21/2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
H	59	JP	10-251142		Michael	9/22/1998		X+
	60	JP	2000-119177		Torii Yakuhin KK	4/25/2000		X+
	61	JP	2002-179562		Towa Yakuhin KK	6/26/2002		X+
	62	PCT	WO 96/32135		Farmarc Nederland BV	10/17/1996		
	63	PCT	WO 02/074200		Cydex, Inc.	9/26/2002		
	64	UK	2 359 747		Maelor Pharmaceuticals Ltd.	9/5/2001		
g								

Examiner Signature

Date Considered

6/04

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 



IDS

12/4/02

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 9/376,487
Filing Date August 18, 1999
First Named Inventor MISHRA
Group Art Unit 1617
Examiner Name E. Webman
Attorney Docket Number 402090

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
J	1	4,056,635		Glen et al.	11/1/1977	
	2	4,280,996		Okamoto et al.	7/28/1981	
	3	4,309,421		Ghyczy et al.	1/5/1982	
	4	4,340,594		Mizushima et al.	7/20/1982	
	5	4,687,762		Fukushima et al.	8/18/1987	
	6	4,837,028		Allen	6/6/1989	
	7	4,880,634		Speiser	11/14/1989	
	8	4,895,726		Curtet et al.	1/23/1990	
	9	5,023,087		Yau-Young	6/11/1991	
	10	5,100,591		Leclef et al.	3/31/1992	
	11	5,320,906		Eley et al.	6/14/1994	
	12	5,527,537		Dietl	6/18/1996	
	13	5,827,520		de Salvert	10/27/1998	
	14	5,827,536		Laruelle	10/27/1998	
	15	5,880,148		Edgar et al.	3/9/1999	
	16					

FOREIGN PATENT DOCUMENTS


Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
J	17	DE	25 13 797		ICI Ltd.	10/9/975		X+
	18	DE	29 38 807		Green Cross Corp.	11/13/1980		X+
	19	DE	3421 468		Rentschler Arzenimittel	12/19/1985		X+
	20	EP	052 322		Gersonde Klaus Prof Dr	5/26/1982		X+
	21	EP	057 829		Fullard	8/18/1982		
	22	EP	272 091		Vestar, Inc.	6/22/1988		
	23	EP	330 532		Fournier Innovation Synergie	8/30/1989		X+
	24	EP	391 369		Yissum Research Dev.	10/10/1990		
	25	EP	418 153		Medgenix Group SA	3/20/1991		X+
	26	EP	456 670		Braun Melsungen AG	11/21/1991		X+
	27	EP	456 764		Braun Melsungen	11/21/1991		X+
	28	EP	499 299		Sterling Winthrop Inc.	8/19/1992		
	29	EP	535 567		Braun Melsungen AG	4/7/1993		X+
	30	EP	570 829		Hans	11/24/1993		X+
	31	EP	601 618		Sterling Winthrop Inc.	6/15/1994		
	32	EP	602 700		Sterling Winthrop Inc.	6/22/1994		
	33	EP	724 877		Fournier Lab SA	8/7/1996		X+
	34	EP	757 911		CLL Pharma	2/12/1997		X+
	35	EP	770 387		B. Braun Melsungen AG	5/2/1997		
	36	EP	770 381		Oreal	5/2/1997		X+


Examiner Signature

Date Considered

6/04

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	9/376,487	
			Filing Date	August 18, 1999	
			First Named Inventor	MISHRA	
			Group Art Unit	1617	
			Examiner Name	E. Webman	
Sheet	2	of	2	Attorney Docket Number	402090

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	37	EP	814 787		AstraZeneca AB	1/7/1998		
	38	EP	1 238 677		AstraZeneca AB	9/11/2002		
	39	FR	2 265 357		ICI Ltd.	10/24/1975		X+
	40	FR	2 617 047		Sanofi SA/Fournier Labs.	12/30/1988		X+
	41	JP	55-141407		Nattermann A & CIE	11/5/1980		X+
	42	JP	56-167616		Green Cross Corp.	12/23/1981		X+
	43	JP	60-208910		Green Cross Corp.	10/21/85		X+
	44	JP	63-502117			8/18/1988		X+
	45	JP	63-233915		Besutaa Res. Inc.	9/29/1988		X+
	46	JP	1-502590		Liposome Tech. Inc.	9/7/1989		X+
	47	HU	211 580		Egis Gyogyszergyar Rt.	12/28/1995		X+
	48	PCT	WO 85/00011		The University of Miami	1/3/1985		
	49	PCT	WO 87/04592		Liposome Tech. Inc.	8/13/1987		
	50	PCT	WO 91/04011		Riker Labs., Inc.	4/4/1991		
	51	PCT	WO 93/19736		Kabi Pharmacia AB	10/14/1993		
	52	PCT	WO 94/20072		Pharmacia AB	9/15/1994		
	53	PCT	WO 96/01637		Astra Aktiebolag	1/25/1996		
	54	PCT	WO 96/19064		Xcellenet, Inc.	6/20/1996		
	55	PCT	WO 96/21439		Galephar P.R. Inc.	7/18/1996		
	56	PCT	WO 96/29064		Zeneca Ltd.	9/26/1996		
	57	PCT	WO 97/10814		Vesifact AG	3/27/1997		
	58	PCT	WO 97/14407		Research Triangle Pharmaceuticals	4/24/1997		
	59	PCT	WO 98/53805		Saucy Ltd.	12/3/1998		
	60	PCT	WO 99/39696		Gensia Sicor Inc.	8/12/1999		
	61	PCT	WO 00/10531		RTP Pharma Inc.	3/2/2000		
	62	PCT	WO 00/24376		Abbott Labs.	5/4/2000		
	63	PCT	WO 00/54588		Krusz	9/21/00		
	64	PCT	WO 00/59471		Baxter International, Inc.	10/12/2000		
	65	PCT	WO 00/59472		Baxter International, Inc.	10/12/2000		
	66	PCT	WO 00/78301		Kuhnli Pharm. Co. Ltd.	12/28/2000		
	67	PCT	WO 01/30372		BASF Aktiengesellschaft	5/3/2001		X+
	68	PCT	WO 02/21517		Zeon Corp.	3/14/2002		X+
	69	UK	2 046 094		A. Nattermann & Cie	11/12/1980		
	70	UK	2 250 197		Egis Gyogyszergyar	6/3/1992		
	71	UK	2 298 789		Zeneca Ltd.	9/18/1996		

Examiner Signature		Date Considered	6/04
--------------------	---	-----------------	------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- * An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

121-272

to be assigned

APPLICANT

MISHRA et al

FILING DATE

GROUP

March 23, 2001

Error! Reference source not found.

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
J	4,056,635	11/1977	Glen et al			
J	5,478,860	12/1995	Wheeler et al			
J	5,589,508	12.1996	Schlotzer et al			
J	5,637,625	6/1997	Haynes			
J	5,688,528	11/1997	Carlsson et al			
J	5,714,520	2/1998	Jones et al			
J	6,028,108	2/2000	George			
J	6,100,302	8/2000	Pejaver et al			
J	6,140,373	10/2000	May et al			
J	6,140,374	10/2000	May et al			
J	6,147,122	11/2000	Mirejovsky et al			
J	6,150,423	11/2000	Carpenter			
J	6,177,477	1/2001	George et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 00/59471	10/2000	WIPO			
WO 00/59472	10/2000	WIPO			
WO 00/78301	12/2000	WIPO			
WO 97/10814	3/1997	WIPO			
WO 98/53805	3/1998	WIPO			
0 770 387 A1	5/1997	Europe			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Cox et al "Influence of different fat emulsion.." Pharmaceutical Research Vol. 15, No. 3, 3/1998, pp 442-448


*Examiner

Date Considered

6/04

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Please type a plus sign (+) inside this box → ☐



IDS 12/10/02

RECEIVED
DEC 11 2002
TECH CENTER 1800/12/02

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/376,487
		Filing Date	August 18, 1999
		First Named Inventor	MISHRA
		Group Art Unit	1617
		Examiner Name	E. Webman
Sheet 1 of 3	Attorney Docket Number	402090/SKYE PHARMA	


OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
J	1	"Diprivan 1% Injection," Physicians' Desk Reference, 1996, pp. 2833-39.		
	2	"Diprivan 1% Injection," Physicians' Desk Reference, 1999, pp. 3411-18.		
	3	Arduino, M.J. et al., "Microbial Growth and Endotoxin Production in the Intravenous Anesthetic Propofol", Infection Control and Hospital Epidemiology, Vol. 12, No. 9, September 1991, pp. 535-539.		
	4	Babi et al., "New Formulations of Propofol in an LCT/MCT Emulsion: Approach to Reduce Pain on Injection", Eur. Hosp. Pharmacy, January 1995, Vol. 1, No. 1, pp. 15-21.		
	5	Bangham et al., "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids," J. Mol. Biol., 1965, 13:238-251.		
	6	Bennett et al., "Postoperative Infections Traced to Contamination of an Intravenous Anesthetic, Propofol", Vol. 333, No. 3, July 20, 1995, pp. 147-154.		
	7	Benz et al., "Electrical Capacity of Black Lipid Films and of Lipid Bilayers made from Monolayers," Biochimica et Biophysica Acta, 1975, 394:323-334.		
	8	Bergmann, Ludwig, Der Ultraschall, 5 Aufl., 1949, Stuttgart, pp. 551-564 and 665-677.		X
	9	Bittman, Robert, "Sterol-Polyene Antibiotic Complexation: Probe of Membrane Structure," LIPIDS, Vol. 13, No. 10, pp. 686-691 (1978).		
	10	Cairns et al., "Tolerance of Mixed Lipid Emulsion in Neonates: Effect of Concentration", Archives of Disease in Childhood, 1996, Vol. 75, p. F113-F116.		
	11	Cherney, Leonid S., "Tetracaine Hydroiodide: A Long-Lasting Local Anesthetic Agent for the Relief of Postoperative Pain," Anesthesia and Analgesia, Vol. 42, No. 4, July-Aug. 1963, pp. 477-481.		
	12	Crowther et al., "Growth of Microorganisms in Propofol, Thiopental and a 1:1 Mixture of Propofol and Thiopental", Anesth. and Anal., (1996), 82, pp. 475-478.		
	13	Cudd et al., "Liposomes Injected Intravenously into Mice Associate with Liver Mitochondria," Biochimica et Biophysica Acta, (1984), 774:169-180.		
	14	De Sommer et al., "A Comparative Study on the Effects of Propofol in Emulsion and Intralipid® on Fat Metabolism," Acta Anesthesiologica Belgica, Vol. 41, No. 2, 1990, pp. 133-138.		
	15	Dewandre et al., "A Comparison of the 2% and 1% Formulations of Propofol During Anaesthesia for Craniotomy," Anesthesia, 1994, Vol. 49, pp. 8-12.		
	16	Doenicke, A.W. et al., "Pharmacokinetics and Pharmacodynamics of Propofol in a New Solvent", Anesth. Analg., (1997), 85:1399-403.		
	17	Doenicke, A.W. et al., "Reducing Pain During Propofol Injection: The Role of the Solvent", Anesth. Analg., (1996), 82:472-4.		

Examiner Signature		Date Considered	6/04
-----------------------	--	--------------------	------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



RECEIVED
DEC 11 2002
TECH CENTER 109012800


Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	09/376,487
		Filing Date	August 18, 1999
		First Named Inventor	MISHRA
		Group Art Unit	1617
		Examiner Name	E. Webman
Sheet	2	of	3
		Attorney Docket Number	402090/SKYEPHARMA

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
M	18	Eddleston et al., "The Effect on Serum Lipid Concentrations of a Prolonged Infusion of Propofol - Hypertriglyceridaemia Associated with Propofol Administration," Intensive Care Med., (1991), 17:424-426.		
	19	Ewart et al., "Forum: 2% Propofol for Sedation in the Intensive Care Unit, A Feasibility Study", Anaesthesia, February 1992, Vol. 47, No. 2, pp. 146-148.		
	20	Freeman, Andrew B., "A Technique for Reducing Pain Associated with Propofol Administration," Anesth. Analg., 1992, 74:311-319.		
	21	Ghouri et al., "Effect of Flumazenil on Recovery after Midazolam and Propofol Sedation", Anesthesiology, (1994), 81:333-339.		
	22	Goodman & Gillman's The Pharmacological Basis of Therapeutics, 7 th Ed., MacMillan Publishing Co., New York, 1985. p.312.		
	23	Gottardis et al., Effect of Prolonged Sedation with Propofol on Serum Triglyceride and Cholesterol Concentrations, British J. Anaesthesia, (1989) 62:393-396.		
	24	Gregoriadis, Gregory, "The Carrier Potential of Liposomes in Biology and Medicine", The New England Journal of Medicine, September 23, 1976, Vol. 295, pp. 704-710.		
	25	Haung et al., "Interaction of the N-terminus of Sterol Carrier Protein 2 with Membranes: Role of Membrane Curvature," Biochem. J., (1999), 344:593-603.		
	26	Haynes et al. "Ultra-Long Duration Local Anesthesia Produced by Intra-Dermal Injection of Lecithin-Coated Methoxyflurane Microdroplets", Proceed. Intern. Symp. Control. Rel. Bioact. Mater., (1987), 14:293-294 (Extended abstract)		
	27	Haynes et al., "Ultra-long-duration Local Anesthesia Produced by Injection of Lecithin-coated Methoxyfluorene Microdroplets", Anesthesiology, November 1985, Vol. 63, No. 5, pp. 490-499.		
	28	Haynes, Duncan H., "Divalent Cation-Ligand Interactions of Phospholipid Membranes: Equilibria and Kinetics," Metal-Ligand Interactions in Organic Chemistry and Biochemistry, Pullman and Goldblum, Eds., part 2, ©1977, pp. 189-212		
	29	King et al., "Lidocaine for the Prevention of Pain Due to Injection of Propofol," Anesth. Analg., 1992, 74:246-249.		
	30	Kirkpatrick et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man," Anesthesiology, 1987, 67(3A):A254, Abstract only.		
	31	Lindholm, Marianne, "Critically Ill Patients and Fat Emulsions," Minerva Anesthesiology, 1992, Vol. 58, No. 10, pp. 875-879.		
	32	Mangar et al., "Tourniquet at 50 mm Hg Followed by Intravenous Lidocaine Diminishes Hand Pain Associated with Propofol Injection", Anesth. Analg., (1992), 74:250-252.		
J	33	Mirakhur et al., "Induction Characteristics of Propofol in Children: Comparison with Thiopentone", Anesthesia, (1998), 43:593-598.		
	34	Mishra et al., "Scientifically Speaking: Novel Injectable Formulations of Water-insoluble Drugs", Controlled Release Newsletter, Vol. 17, Issue 2, June 2000, pp.21-30		
	35	Nichols, Ronald Lee, "Bacterial Contamination of an Anesthetic Agent," New Engl. J. Med., (1995), 333(3), 184-185.		

Examiner Signature		Date Considered	6/04
--------------------	--	-----------------	------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → +



FCH CENTER 160012900

DEC 11 2002

RECEIVED

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/376,487
Filing Date	August 18, 1999
First Named Inventor	MISHRA
Group Art Unit	1617
Examiner Name	E. Webman
Attorney Docket Number	402090/SKYE PHARMA

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
<i>J</i>	36	Rompp, "Emulsion", Chemie-Lexikon, 2 Aufl., Bd. 1, 1950, Stichwort.		
<i>J</i>	37	Ross, et al., "Aqueous Solutions of Surface-Active Solutes", Colloidal Systems and Interfaces, © 1988, p. 148-151		X
	38	Sande et al., "Antimicrobial Agents: Antifungal and Antiviral Agents," p. 1219-1222.		
	39	Sandstrom et al., "Structured Triglycerides Were Well Tolerated and Induced Increased Whole Body Fat Oxidation Compared With Long-Chain Triglycerides in Postoperative Patients," Journal of Parenteral and Enteral Nutrition, (1995), 19(5):381-6.		
	40	Sklar, Grant E., "Propofol and Postoperative Infections," The Annals of Pharmacotherapy, (1997), 31:1521-3.		
	41	Smith et al., "Propofol: An Update on its Clinical Use," Anesthesiology, Oct. 1994, Vol. 81, No. 4, pp. 1005-1043.		
	42	Sosis et al., "Growth of Staphylococcus aureus in Four Intravenous Anesthetics," Anesth. Anal., (1993), Vol. 77, pp. 766-768		
	43	Sosis et al., "Propofol, but not Thiopental, Supports the Growth of Candida albicans," Anesth. Anal., (1995), Vol. 81, pp. 132-134.		
	44	Stark, et al., "A review of the safety and tolerance of propofol ('Diprivan')", Postgraduate Medical Journal, 1985, Vol. 61, Suppl. 3, pp. 152-156.		
	45	Stenz et al., "A new physiologically approached in vitro test for quick evaluation of the hemolytic activity of surfactants," Pharmazie, (1996), 51(5), pp. 283-287.		
	46	Tessler et al., "Growth curves of Staphylococcus aureus, Candida albicans, and Moraxella osloensis in propofol and other media", Can. J. Anaesth., 1992, 39 (5), pp. 509-511.		
	47	White et al., "Sedative Infusions During Local and Regional Anesthesia: A Comparison of Midazolam and Propofol", J. Clin. Anesth., Jan/Feb 1991, Vol. 3, pp. 32-39.		
<i>J</i>	48	Wu et al., "Pharmacokinetics of Methoxyflurane after its Intra-dermal Injection as Lecithin-Coated Microparticles", Journal of Controlled Release, 1989, Vol. 9, pp. 1-12.		

Examiner Signature	<i>[Signature]</i>	Date Considered	6/04
-----------------------	--------------------	--------------------	------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).